{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T21:01:27Z","timestamp":1764277287899,"version":"3.40.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105757","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:46:14Z","timestamp":1719967574000},"page":"105757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-5285","authenticated-orcid":false,"given":"Abdulkadir","family":"Tun\u00e7","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Fatih","family":"Yetkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"Sefero\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u0131lmaz","family":"\u0130nan\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali \u00d6zhan","family":"S\u0131vac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eule Ayd\u0131n","family":"T\u00fcrko\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caner","family":"Baydar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vildan","family":"G\u00fczel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazl\u0131 Gamze","family":"B\u00fclb\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasfiye","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya\u015far","family":"Altun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.msard.2024.105757_bib0001","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","article-title":"Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study","volume":"86","author":"Barbin","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105757_bib0002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2024.105757_bib0003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.msard.2024.105757_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221150312","article-title":"Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis","volume":"16","author":"Cerd\u00e1-Fuertes","year":"2023","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"10.1016\/j.msard.2024.105757_bib0005","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105757_bib0006","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/1352458518763095","article-title":"Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation","volume":"24","author":"Giordana","year":"2018","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2024.105757_bib0007","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/ene.15913","article-title":"Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: five-year clinical outcomes","volume":"30","author":"Gulec","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105757_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2016.11.003","article-title":"Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis","volume":"11","author":"G\u00fcnd\u00fcz","year":"2017","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2024.105757_bib0009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105757_bib0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamaneurol.2014.4147","article-title":"Comparison of switch to fingolimod or interferon beta\/glatiramer acetate in active multiple sclerosis","volume":"72","author":"He","year":"2015","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105757_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2024.105757_bib0012","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-021-10658-8","article-title":"What happens after fingolimod discontinuation? A multicentre real-life experience","volume":"269","author":"Landi","year":"2021","journal-title":"J. Neurol."},{"issue":"Pt 9","key":"10.1016\/j.msard.2024.105757_bib0013","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain J Neurol"},{"issue":"3","key":"10.1016\/j.msard.2024.105757_bib0014","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105757_bib0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2024.105757_bib0016","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1212\/NXI.0000000000000377","article-title":"Dramatic rebounds of MS during pregnancy following fingolimod withdrawal","volume":"4","author":"Novi","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"10.1016\/j.msard.2024.105757_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102918","article-title":"Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment","volume":"51","author":"Pantazou","year":"2021","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"6","key":"10.1016\/j.msard.2024.105757_bib0018","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/1352458511431073","article-title":"Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped","volume":"18","author":"Rispens","year":"2012","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2024.105757_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2024.105757_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2018.07.001","article-title":"Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases","volume":"25","author":"S\u00e1nchez","year":"2018","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2024.105757_bib0021","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2169\/internalmedicine.0793-18","article-title":"Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis","volume":"57","author":"Sato","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2024.105757_bib0022","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ene.12195","article-title":"Rebound of disease activity during pregnancy after withdrawal of fingolimod","volume":"20","author":"Sempere","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105757_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101483","article-title":"Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: analysis of predisposing factors","volume":"38","author":"Sep\u00falveda","year":"2020","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2024.105757_bib0024","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105757_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105757_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/NRL.0000000000000154","article-title":"Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation","volume":"23","author":"Uygunoglu","year":"2018","journal-title":"Neurologist"},{"key":"10.1016\/j.msard.2024.105757_bib0027","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.105757_bib0028","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: are we helping or hurting?","volume":"68","author":"West and Cree","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105757_bib0029","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1212\/NXI.0000000000000320","article-title":"An observational study of alemtuzumab following fingolimod for multiple sclerosis","volume":"4","author":"Willis","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.msard.2024.105757_bib0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.autrev.2017.02.007","article-title":"Multiple sclerosis in the real world: a systematic review of fingolimod as a case study","volume":"16","author":"Ziemssen","year":"2017","journal-title":"Autoimmun. Rev."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:22:28Z","timestamp":1723605748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"alternative-id":["S2211034824003341"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105757","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurring disease activity in relapsing remitting multiple sclerosis: The multicenter RDA-RMS study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105757"}}